Immuno-Oncology Outlook: Bavencio Leads PD-1/L1 Pack In Ovarian Cancer

 
• By Lucie Ellis-Taitt
  
Arrows
All marketed PD-1/L1 drugs have ovarian cancer trials ongoing but Bavencio leads the charge • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D